The aim of the proposed study is to better understand the central factors involved in the etiopathogenesis of altered pain perception in fibromyalgia (FM). We will test six hypotheses drawn from a model which posits that neuroendocrine and immunologic abnormalities, characterized by decreases in cerebrospinal fluid (CSF) serotonin and increases in CSF substance P (SP), lead to sensitization of central nervous system structures involved in pain perception, i.e., thalamus and caudate nucleus. Decreases in regional cerebral blood flow (rCBF) to these structures serve as markers for this sensitization process and are associated with generalized low pain thresholds and other alterations in pain perception, independently of the effects of psychiatric morbidity or psychological status. The model also posits that elevated CSF SP may in part be due to SP messenger (m) RNA production by CSF leukocytes. We propose to measure (l) rCBF to cortex, thalamus, and caudate nucleus, (2) CSF levels of serotonin metabolite 5-hydroxyindole acetic acid (5-HIAA), SP, CSF leukocyte number, and leukocyte SP mRNA level, (3) pain thresholds and indices of sensory discrimination ability and response bias in response to dolorimeter stimulation of tender and control points, and (4) psychological status and number of lifetime psychiatric diagnoses. These variables will be assessed using (l) 80 patients with FM by American College of Rheumatology (ACR) criteria drawn from the Rheumatology clinics at UAB and Cooper Green Hospital (""""""""Patients""""""""), (2) 50 community residents of comparable age, gender, education, and race with musculoskeletal pain who fulfill ACR criteria for FM, but who have not sought medical care for their symptoms in the past 10 years (""""""""Non-Patients""""""""), and (3) 50 community residents of comparable demographic features without musculoskeletal pain who do not fulfill ACR criteria for FM (""""""""Controls""""""""). The use of non- patients, who do not differ from controls in psychiatric morbidity, will allow us to determine if altered levels of rCBF to the thalamus and caudate nucleus are associated with pain perception and neurochemical levels regardless of subjects' psychiatric histories. This study is the first to examine relationships among rCBF to central structures and neurotransmitters involved in pain perception and subjects' responses to noxious stimuli while controlling for psychological variables. The results of this study will advance our knowledge regarding the roles of the central nervous system and neuroendocrine and immunologic abnormalities involved in altered pain perception among patients and community residents with FM. In addition, the results of the project may lead to development of pharmacologic interventions that will normalize rCBF to central brain structures and thus decrease pain among patients with FM.
| Bradley, Laurence A (2005) Psychiatric comorbidity in fibromyalgia. Curr Pain Headache Rep 9:79-86 |
| Sprott, H; Salemi, S; Gay, R E et al. (2004) Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres. Ann Rheum Dis 63:245-51 |
| Bradley, Laurence A; McKendree-Smith, Nancy L; Alarcon, Graciela S et al. (2002) Is fibromyalgia a neurologic disease? Curr Pain Headache Rep 6:106-14 |
| Kersh, B C; Bradley, L A; Alarcon, G S et al. (2001) Psychosocial and health status variables independently predict health care seeking in fibromyalgia. Arthritis Rheum 45:362-71 |
| Bradley, L A; McKendree-Smith, N L; Alberts, K R et al. (2000) Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Curr Rheumatol Rep 2:141-8 |
| Bradley, L A; McKendree-Smith, N L; Alarcon, G S (2000) Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome. Curr Rev Pain 4:148-57 |
| Bradley, L A; Alberts, K R (1999) Psychological and behavioral approaches to pain management for patients with rheumatic disease. Rheum Dis Clin North Am 25:215-32, viii |
| Mountz, J M; Bradley, L A; Alarcon, G S (1998) Abnormal functional activity of the central nervous system in fibromyalgia syndrome. Am J Med Sci 315:385-96 |
| Weigent, D A; Bradley, L A; Blalock, J E et al. (1998) Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci 315:405-12 |
| Alarcon, G S; Bradley, L A (1998) Advances in the treatment of fibromyalgia: current status and future directions. Am J Med Sci 315:397-404 |
Showing the most recent 10 out of 13 publications
